Educational Session Focused on Actimab-A and the Role of Radiopharmaceuticals in Hematologic Malignancies

NEW YORK-- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Actinium’s Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming educational session highlighting the role of radiopharmaceuticals, including Actimab-A, in the treatment of acute myeloid leukemia (AML) and in other cancers. The conference will be held Friday, May 30 – Wednesday June 3, 2014 at McCormick Place, Chicago, IL.

The schedule for the panel is as follows:

Date: Sunday, June 1, 2014
Time: 9:45 AM – 11:00 AM
Room: S100a
Session Title: “Radiopharmaceuticals: Spanning Hematologic Malignancies to Solid Tumors”

Actimab-A is a radiolabeled antibody being developed for newly diagnosed AML in patients over 60, and is currently in a multicenter Phase 1/2 clinical trial with Dr. Jurcic as the Principal Investigator. Based on Actinium’s alpha-particle immunotherapy (APIT) platform, Actimab-A consists of the CD33 antibody Lintuzumab linked to the actinium-225 payload. The Company expects interim Phase 2 results in late 2014. Additional Actimab candidates are in early development for other cancers. Actimab-A has attracted support from leading experts at the most prestigious and high-volume cancer treatment hospitals due to the potential of its safety and efficacy profile, as well as its potency, specificity and ease of use.

Dr. Jurcic is Director of the Hematologic Malignancies Section of the Hematology/Oncology Division and a Professor of Medicine at Columbia University Medical Center in New York. He is a hematologist/oncologist focusing on the treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome. His research interests include acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody therapy for leukemia, development of novel small molecule inhibitors for leukemia and molecular monitoring of minimal residual disease. He received his medical degree from the University of Pennsylvania and completed his fellowship in Hematology-Oncology at Memorial Sloan Kettering Cancer Center. In addition to Chairing Actinium’s Clinical Advisory Board, Dr. Jurcic is the Lead Investigator for the Company’s Actimab-A trials.

“Alpha emitters offer the possibility of more efficient leukemia cell killing without the toxicity of intensive chemotherapy,” said Dr. Jurcic. “We are now studying this modality in combination with low-dose chemotherapy in older AML patients. Because many of these patients cannot tolerate intensive chemotherapy, new treatments are desperately needed. The use of Actimab-A could potentially avoid the toxicities associated with standard treatments.”

The panel discussion will be chaired by George Sgouros, PhD, Professor of Radiology, Oncology and Radiation Oncology, Director of Radiopharmaceutical Dosimetry Section of the Division of Nuclear Medicine, Johns Hopkins University School of Medicine. The other panel participant is Dr. Sten Nilsson of the Karolinska Institute who has previously spoken on the use of radium-223 in solid tumors by Algeta ASA.

ASCO is the pre-eminent clinical cancer meeting in the U.S., and 2014 marks its 50th Annual Meeting, bringing together more than 25,000 oncology professionals. ASCO is a professional oncology society committed to conquering cancer through research, education, prevention, and delivery of high-quality patient care. For further information, please visit asco.org.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Actinium Pharmaceuticals, Inc.
Evan Smith, CFA, 646-840-5442
VP Investor Relations and Finance
esmith@actiniumpharma.com

Source: Actinium Pharmaceuticals, Inc.

Released May 20, 2014